



21 January 2026  
EMA/CAT/13322/2026  
Human Medicines Division

## Committee for Advanced Therapies (CAT)

Draft agenda for the meeting on 21-23 January 2026

Chair: Ilona Reischl-Kok; Vice-Chair: Kieran Breen

21 January 2026, 14:00 – 18:30

22 January 2026, 09:00 – 18:30

23 January 2026, 09:00 – 13:00

### Health and safety information

In accordance with the Agency's health and safety policy, delegates are to be briefed on health, safety and emergency information and procedures prior to the start of the meeting.

### Disclaimers

Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CAT meeting reports once the procedures are finalised.

Of note, this agenda is a working document primarily designed for CAT members and the work the Committee undertakes.

### Note on access to documents

Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).



## Table of contents

|  |          |
|--|----------|
| <b>1. Introduction</b>   | <b>5</b> |
| 1.1. Welcome and declarations of interest of members, alternates and experts .....   | 5        |
| 1.2. Adoption of agenda .....  | 5        |
| 1.3. Adoption of the minutes .....   | 5        |
| <b>2. Evaluation of ATMPs</b>  | <b>5</b> |
| 2.1. Opinions .....  | 5        |
| 2.2. Oral explanations .....   | 5        |
| 2.3. Day 180 list of outstanding issues .....  | 5        |
| 2.4. Day 120 list of questions .....   | 5        |
| 2.5. Day 80 assessment reports .....   | 5        |
| 2.6. Update on ongoing initial applications .....  | 5        |
| 2.7. New applications .....  | 6        |
| 2.8. Withdrawal of initial marketing authorisation application .....   | 6        |
| 2.9. Re-examination of initial application procedures under Article 9(2) of Regulation No. 726/2004 .....                              | 6        |
| 2.10. GMP and GCP inspections requests .....   | 6        |
| 2.11. Type II variations and variations of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008 ..... | 6        |
| 2.11.1. Breyanzi - Lisocabtagene maraleucel - Orphan - EMA/VR/0000258227 .....   | 6        |
| 2.11.2. Breyanzi - Lisocabtagene maraleucel - Orphan - EMA/VR/0000313331 .....   | 6        |
| 2.11.3. CARVYKTI - Ciltacabtagene autoleucel - Orphan - EMA/VR/0000290398 .....  | 6        |
| 2.11.4. YesCarta - Axicabtagene ciloleucel - Orphan - EMA/VR/0000313321 .....  | 7        |
| 2.11.5. Hemgenix - Etranacogene dezaparvovec - EMA/VR/0000308793 .....   | 7        |
| 2.12. Extension applications .....   | 7        |
| 2.13. Other Post-Authorisation Activities .....  | 7        |
| 2.13.1. CARVYKTI - Ciltacabtagene autoleucel - Orphan - EMA/PAM/0000286337 .....   | 7        |
| 2.13.2. CARVYKTI - Ciltacabtagene autoleucel - Orphan - EMA/PAM/0000308135 .....   | 7        |
| 2.13.3. Hemgenix - Etranacogene dezaparvovec - Orphan - EMA/PAM/0000248926 .....   | 8        |
| 2.13.4. Zemcelpro - Dorocubicel / Allogeneic umbilical cord-derived CD34- cells, non-expanded - Orphan - EMA/PAM/0000308204 .....      | 8        |
| 2.14. Companion diagnostics - initial consultation .....   | 8        |
| 2.15. Companion diagnostics - Follow-up consultation .....   | 8        |
| <b>3. Certification of ATMPs</b>   | <b>8</b> |
| 3.1. Opinion .....   | 8        |
| 3.2. Day 60 Evaluation Reports .....   | 8        |
| 3.3. New Applications .....  | 8        |

|  |           |
|--|-----------|
| <b>4. Scientific Recommendation on Classification of ATMPs</b>   | <b>8</b>  |
| <b>4.1. New requests – Appointment of CAT Coordinator .....</b>  | <b>9</b>  |
| 4.1.1. Live attenuated Listeria monocytogenes bearing plasmids encoding the recombinant chimeric fusion protein of truncated nonhemolytic listerolysin O (tLLO) and a tumour associated antigen (TAA) comprised of two extracellular (EC1 and EC2) and one intracellular (IC1) fragments of the human Her2/neu protein ..... | 9         |
| 4.1.2. Allogeneic Umbilical Cord-derived Mesenchymal Stem Cells .....  | 9         |
| 4.1.3. Autologous chimeric antigen receptor T cells against epidermal growth factor variant III (EGFRvIII) and messenger ribonucleic acid vaccine lipoplexes encoding EGFRvIII (intracerebroventricular administration) .....  | 9         |
| 4.1.4. Autologous chimeric antigen receptor T cells against epidermal growth factor variant III (EGFRvIII) and messenger ribonucleic acid vaccine lipoplexes encoding EGFRvIII (intravenous administration).....   | 9         |
| 4.1.5. Extracellular vesicles from Wharton Jelly hTERT- expressing Mesenchymal Stromal Cells (MSCs) loaded with the micro-RNA miR-140 .....  | 9         |
| <b>4.2. Day 30 ATMP scientific recommendation .....</b>  | <b>10</b> |
| 4.2.1. Red blood cells derived from immortalised hematopoietic progenitors.....  | 10        |
| 4.2.2. Platelets derived from immortalised hematopoietic progenitors.....  | 10        |
| 4.2.3. Allogeneic human induced pluripotent stem cell (hiPSC)-derived midbrain dopaminergic (mDA) neuronal progenitor cells .....  | 10        |
| <b>4.3. Day 60 revised scientific recommendation (following list of questions) .....</b>   | <b>10</b> |
| <b>4.4. Finalisation of procedure .....</b>  | <b>10</b> |
| <b>4.5. Follow-up and guidance.....</b>  | <b>10</b> |
| <b>5. Scientific Advice</b>  | <b>10</b> |
| <b>5.1. New requests - appointment of CAT Rapporteurs .....</b>  | <b>11</b> |
| 5.1.1. Ongoing scientific advice procedures - Appointment of CAT Peer Reviewers.....   | 11        |
| 5.1.2. Scientific advice procedures starting at the next SAWP meeting.....   | 11        |
| <b>5.2. Procedures discussed at SAWP – 1st reports, D40 JRs, LoIs .....</b>  | <b>11</b> |
| <b>5.3. Finalisation of D70 procedures – feedback from the discussion meeting.....</b>   | <b>11</b> |
| <b>5.4. Final Advice Letters for procedures finalised the previous month.....</b>  | <b>11</b> |
| <b>6. Pre-Authorisation Activities</b>   | <b>11</b> |
| <b>6.1. Paediatric investigation plans.....</b>  | <b>11</b> |
| <b>6.2. ITF briefing meetings in the field of ATMPs .....</b>  | <b>11</b> |
| <b>6.3. Priority Medicines (PRIME) – Eligibility requests.....</b>   | <b>12</b> |
| 6.3.1. Month 0 - Start of the procedure.....   | 12        |
| 6.3.2. Month 1 – Discussion of eligibility.....  | 12        |
| 6.3.3. Month 2 – Recommendation of eligibility .....   | 12        |
| 6.3.4. Ongoing support.....  | 12        |
| <b>7. Organisational, regulatory and methodological matters</b>  | <b>12</b> |
| <b>7.1. Mandate and organisation of the CAT .....</b>  | <b>12</b> |

|             |  |           |
|-------------|--|-----------|
| 7.1.1.      | CAT membership .....   | 12        |
| 7.1.2.      | CAT Strategic Review & Learning meeting (SRLM) under the Cypriot presidency .....  | 12        |
| 7.1.3.      | Election of CAT Chair person 2026.....   | 12        |
| <b>7.2.</b> | <b>Coordination with EMA Scientific Committees.....</b>  | <b>12</b> |
| <b>7.3.</b> | <b>Coordination with EMA Working Parties/Working Groups/Drafting Groups .....</b>  | <b>13</b> |
| <b>7.4.</b> | <b>Cooperation with the EU regulatory network.....</b>   | <b>13</b> |
| 7.4.1.      | Webinar on the use of platform technologies in the non-clinical and clinical domains.....  | 13        |
| 7.4.2.      | Mandate of Novel therapies ESEC.....   | 13        |
| <b>7.5.</b> | <b>Cooperation with international regulators .....</b>   | <b>13</b> |
| 7.5.1.      | ATMP cluster teleconference with US-FDA, Health Canada, PMDA (Japan) and Swissmedic  | 13        |
| <b>7.6.</b> | <b>CAT work plan .....</b>   | <b>13</b> |
| 7.6.1.      | CAT Workplan 2026 .....  | 13        |
| <b>7.7.</b> | <b>Planning and reporting .....</b>  | <b>13</b> |
| 7.7.1.      | Q4-2025 Business Pipeline report for the human scientific committees .....   | 13        |
| <b>7.8.</b> | <b>Others .....</b>  | <b>14</b> |
| 7.8.1.      | Progression updates and expansion of the scope for the revision of the ATMP GMP guideline  | 14        |
| 7.8.2.      | Questions and answers on the use of out-of-specification batches of authorised cell/tissue-based advanced therapy medicinal products (EMA/CAT/224381/2019) ..... | 14        |
| 7.8.3.      | REVAMP update.....   | 14        |
| <b>8.</b>   | <b>Any other business</b>  | <b>14</b> |
| <b>9.</b>   | <b>Explanatory notes</b>   | <b>15</b> |

## **1. Introduction**

### **1.1. Welcome and declarations of interest of members, alternates and experts**

Pre-meeting list of participants and restrictions in relation to declarations of interests applicable to the items of the agenda for the CAT plenary session to be held 21-23 January 2026. See January 2026 CAT minutes (to be published post February 2026 CAT meeting).

### **1.2. Adoption of agenda**

CAT agenda for 21-23 January 2026 meeting

### **1.3. Adoption of the minutes**

CAT minutes for 03-05 December 2025 meeting

## **2. Evaluation of ATMPs**

### **2.1. Opinions**

No items

### **2.2. Oral explanations**

No items

### **2.3. Day 180 list of outstanding issues**

No items

### **2.4. Day 120 list of questions**

No items

### **2.5. Day 80 assessment reports**

No items

### **2.6. Update on ongoing initial applications**

No items

## **2.7. New applications**

No items

## **2.8. Withdrawal of initial marketing authorisation application**

No items

## **2.9. Re-examination of initial application procedures under Article 9(2) of Regulation No. 726/2004**

No items

## **2.10. GMP and GCP inspections requests**

No items

## **2.11. Type II variations and variations of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008**

### **2.11.1. Breyanzi - Lisocabtagene maraleucel – Orphan - EMA/VR/0000258227**

---

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Concetta Quintarelli

Scope: Quality, opinion

**Action:** for adoption

### **2.11.2. Breyanzi - Lisocabtagene maraleucel – Orphan - EMA/VR/0000313331**

---

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Concetta Quintarelli

Scope: Quality, opinion

**Action:** for adoption

### **2.11.3. CARVYKTI - Ciltacabtagene autoleucel - Orphan - EMA/VR/0000290398**

---

Janssen Cilag International

Rapporteur: Attila Sebe

Scope: Quality

**Action:** for adoption

#### 2.11.4. Yescarta - Axicabtagene ciloleucel – Orphan - EMA/VR/0000313321

---

Kite Pharma EU B.V.

Rapporteur: Attila Sebe

Scope: Quality, request for supplementary information

**Action:** for adoption

#### 2.11.5. Hemgenix - Etranacogene dezaparvovec - EMA/VR/0000308793

---

CSL Behring GmbH

Rapporteur: Silke Dorner

Scope: Clinical, opinion

Update of sections 4.4, 4.8, 5.1, 5.2, and 6.6 of the SmPC concerning clinical pharmacology, efficacy and safety based on final results from study AMT 061-02 / CSL222\_3001 listed as a specific obligation in the Annex II; this is a phase III, open-label, single-dose, multi-center multinational trial investigating a serotype 5 adeno-associated viral vector containing the Padua variant of a codon-optimized human factor IX gene (AAV5-hFIXco-Padua, AMT-061) administered to adult subjects with severe or moderately severe haemophilia B; the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet and to introduce editorial changes to the PI.

**Action:** for adoption

### 2.12. Extension applications

No items

### 2.13. Other Post-Authorisation Activities

#### 2.13.1. CARVYKTI - Ciltacabtagene autoleucel – Orphan - EMA/PAM/0000286337

---

Janssen Cilag International

Rapporteur: Attila Sebe, PRAC Rapporteur: Jo Robays

Scope: PAM, opinion

**Action:** for adoption

#### 2.13.2. CARVYKTI - Ciltacabtagene autoleucel – Orphan - EMA/PAM/0000308135

---

Janssen Cilag International

Rapporteur: Attila Sebe

Scope: PAM, opinion

**Action:** for adoption

#### **2.13.3. Hemgenix - Etranacogene dezaparvovec – Orphan - EMA/PAM/0000248926**

---

CSL Behring GmbH

Rapporteur: Silke Dorner, PRAC Rapporteur: Bianca Mulder

Scope: PAM, opinion

**Action:** for adoption

#### **2.13.4. Zemcelpro - Dorocubicel / Allogeneic umbilical cord-derived CD34- cells, non-expanded – Orphan - EMA/PAM/0000308204**

---

Cordex Biologics International Limited

Rapporteur: Emmely de Vries

Scope: PAM, request for supplementary information

**Action:** for adoption

### **2.14. Companion diagnostics - initial consultation**

No items

### **2.15. Companion diagnostics – Follow-up consultation**

No items

## **3. Certification of ATMPs**

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

### **3.1. Opinion**

No items

### **3.2. Day 60 Evaluation Reports**

### **3.3. New Applications**

No items

## **4. Scientific Recommendation on Classification of ATMPs**

Timetable:

|   |            |
|---|------------|
| -Start of the procedure:                        | 23.01.2026 |
| -EMA Coordinator's draft report:                | 06.02.2026 |
| -CAT Coordinator's comments:                    | 11.02.2026 |
| -Revised scientific recommendation:             | 13.02.2026 |
| -CAT's discussion of scientific recommendation: | 20.02.2026 |

## 4.1. New requests – Appointment of CAT Coordinator

4.1.1. Live attenuated Listeria monocytogenes bearing plasmids encoding the recombinant chimeric fusion protein of truncated nonhemolytic listerolysin O (tLLO) and a tumour associated antigen (TAA) comprised of two extracellular (EC1 and EC2) and one intracellular (IC1) fragments of the human Her2/neu protein

Treatment of pulmonary recurrence of resected osteosarcoma

Scope: for nomination of CAT coordinator

**Action:** for adoption

4.1.2. Allogeneic Umbilical Cord-derived Mesenchymal Stem Cells

Treatment of lupus nephritis (LN) and systemic lupus erythematosus (SLE)

Scope: for nomination of CAT coordinator

**Action:** for adoption

4.1.3. Autologous chimeric antigen receptor T cells against epidermal growth factor variant III (EGFRvIII) and messenger ribonucleic acid vaccine lipoplexes encoding EGFRvIII (intracerebroventricular administration)

Treatment of EGFRvIII-positive glioblastoma

Scope: for nomination of CAT coordinator

**Action:** for adoption

4.1.4. Autologous chimeric antigen receptor T cells against epidermal growth factor variant III (EGFRvIII) and messenger ribonucleic acid vaccine lipoplexes encoding EGFRvIII (intravenous administration)

Treatment of EGFRvIII-positive glioblastoma

Scope: for nomination of CAT coordinator

**Action:** for adoption

4.1.5. Extracellular vesicles from Wharton Jelly hTERT- expressing Mesenchymal Stromal Cells (MSCs) loaded with the micro-RNA miR-140

Treatment of osteoarthritis

Scope: for nomination of CAT coordinator

**Action:** for adoption

## 4.2. Day 30 ATMP scientific recommendation

### 4.2.1. Red blood cells derived from immortalised hematopoietic progenitors

---

Blood transfusion

Scope: ATMP scientific recommendation

**Action:** for adoption

### 4.2.2. Platelets derived from immortalised hematopoietic progenitors

---

Platelet transfusion

Scope: ATMP scientific recommendation

**Action:** for adoption

### 4.2.3. Allogeneic human induced pluripotent stem cell (hiPSC)-derived midbrain dopaminergic (mDA) neuronal progenitor cells

---

Treatment of Parkinson's disease

Scope: ATMP scientific recommendation

**Action:** for adoption

## 4.3. Day 60 revised scientific recommendation (following list of questions)

No items

## 4.4. Finalisation of procedure

No items

## 4.5. Follow-up and guidance

No items

## 5. Scientific Advice

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

## **5.1. New requests - appointment of CAT Rapporteurs**

### **5.1.1. Ongoing scientific advice procedures - Appointment of CAT Peer Reviewers**

---

Timetable:

|   |               |
|---|---------------|
| - Start of procedure at SAWP:             | 12-15.01.2025 |
| - Appointment of CAT Peer Reviewers:      | 21-23.01.2025 |
| - SAWP first reports:                     | 02.02.2026    |
| - CAT Peer Reviewer comments (NC & C):    | 06.02.2026    |
| - CAT Peer Reviewer comments (Q):         | 11.02.2023    |
| - Discussion at SAWP:                     | 09-12.02.2026 |
| - Discussion at CAT and feedback to SAWP: | 18-20.02.2026 |

### **5.1.2. Scientific advice procedures starting at the next SAWP meeting**

---

Timetable:

|   |               |
|---|---------------|
| - Start of procedure at SAWP:             | 09-12.02.2026 |
| - Appointment of CAT Peer Reviewers:      | 18-20.02.2026 |
| - SAWP first reports:                     | 02.03.2026    |
| - CAT Peer Reviewer comments (NC & C):    | 06.03.2026    |
| - CAT Peer Reviewer comments (Q):         | 11.03.2026    |
| - Discussion at SAWP:                     | 09-12.03.2026 |
| - Discussion at CAT and feedback to SAWP: | 18-20.03.2026 |

## **5.2. Procedures discussed at SAWP – 1st reports, D40 JRs, LoIs**

## **5.3. Finalisation of D70 procedures – feedback from the discussion meeting**

No items

## **5.4. Final Advice Letters for procedures finalised the previous month**

## **6. Pre-Authorisation Activities**

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

### **6.1. Paediatric investigation plans**

No items

### **6.2. ITF briefing meetings in the field of ATMPs**

No items

## 6.3. Priority Medicines (PRIME) – Eligibility requests

### 6.3.1. Month 0 - Start of the procedure

---

Timetable for assessment:

Procedure start: 12-15.01.2026

SAWP recommendation: 12.02.2026

CAT recommendation: 20.02.2026

CHMP adoption of report and final recommendation: 26.02.2026

### 6.3.2. Month 1 – Discussion of eligibility

---

### 6.3.3. Month 2 – Recommendation of eligibility

---

### 6.3.4. Ongoing support

---

No items

## 7. Organisational, regulatory and methodological matters

### 7.1. Mandate and organisation of the CAT

#### 7.1.1. CAT membership

---

**Action:** for information

#### 7.1.2. CAT Strategic Review & Learning meeting (SRLM) under the Cypriot presidency

---

Scope: Preparation for the meeting

CAT: Rafaella Pontou

**Action:** for information

#### 7.1.3. Election of CAT Chair person 2026

---

**Action:** for adoption

### 7.2. Coordination with EMA Scientific Committees

No items

### **7.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups**

No items

### **7.4. Cooperation with the EU regulatory network**

#### **7.4.1. Webinar on the use of platform technologies in the non-clinical and clinical domains**

---

Scope: Agenda & information on the upcoming webinar on 02.03.2026, 9:30 – 12:30

**Action:** for information

#### **7.4.2. Mandate of Novel therapies ESEC**

---

Setting up a novel therapies & technologies European Specialised Expert Communities (ESEC) in the veterinary domain

**Action:** for information

### **7.5. Cooperation with international regulators**

#### **7.5.1. ATMP cluster teleconference with US-FDA, Health Canada, PMDA (Japan) and Swissmedic**

---

CAT: Ilona Reischl

Scope: Agenda of the ATMP cluster of 29.01.2026

**Action:** for information

### **7.6. CAT work plan**

#### **7.6.1. CAT Workplan 2026**

---

Scope: Work plan topics for 2026

CAT: Ilona Reischl

**Action:** for adoption

### **7.7. Planning and reporting**

#### **7.7.1. Q4-2025 Business Pipeline report for the human scientific committees**

---

Scope: Q4-2025 Business Pipeline report for the human scientific committees

**Action:** for information

## 7.8. Others

### 7.8.1. Progression updates and expansion of the scope for the revision of the ATMP GMP guideline

Scope: Proposal for voiding the site of physical import of ATMPs in relation to the general requirements for import of medicinal product from third countries into the EU directly to the clinical site rather than to the importation site.

BWP and CAT to endorse to expand the scope for revision (to include a proposal for waiver of site of physical importation)

Rapporteur: Jean Luc Golnez

**Action:** for adoption

### 7.8.2. Questions and answers on the use of out-of-specification batches of authorised cell/tissue-based advanced therapy medicinal products (EMA/CAT/224381/2019)

Scope: Proposal to amend the Q&A with the revised process for notification of out-of-specification (OOS) ATMPs

**Action:** for discussion

### 7.8.3. REVAMP update

Scope: Overview of upcoming updates, including for the review of the product information.

**Action:** for information

## 8. Any other business

No items

Date of next CAT meeting:

18-20 February 2026

## 9. Explanatory notes

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

### Abbreviations in Committee CMD documents and in relation to EMA regulatory activities


#### **Evaluation of ATMPs (section 2)**

This section lists applications for marketing authorisations of new Advanced Therapy Medicinal Products (ATMPs) that are to be discussed by the Committee. It also lists Post-authorisation activities (section 2.11-2.13) and any ATMP related inspection requests (section 2.14).

#### *New applications (sections 2.1. to 2.9.)*

Section 2.1 is for ATMPs nearing the end of the evaluation and for which the CAT is expected to adopt a draft **opinion** at this meeting on whether marketing authorisation should be granted. Once adopted, the CAT opinion is transmitted to the CHMP for final adoption. The CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU. More information on the evaluation of ATMPs can be found [here](#).

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:



The assessment of an application for a new medicine takes up to 210 'active' days. This active evaluation time is interrupted by at least one 'clock-stop' during which time the applicant prepares the answers to questions from the CAT. The clock stop happens after day 120 and may also happen after day 180, when the CAT has adopted respectively a **Day 120 list of questions** (section 2.4) or a List of outstanding issues to be addressed by the company, which is listed in the agenda under sections 2.7 (**Ongoing evaluation procedures** (section 2.3). Section 2.6 also includes the CAT discussions at any other timepoint of the evaluation procedure of new applications.

#### *Oral explanation (section 2.2.)*

Prior to adoption of the CAT opinion, marketing authorisation applicants are normally invited to the CAT plenary meeting to address questions raised by the Committee.

Oral explanations normally relate to ongoing applications, but they can also relate to any other issue for which the CAT would like to discuss with company representatives in person.

## *New applications (section 2.7.)*

In this section, information is included on upcoming marketing authorisation applications for ATMPs, as well as information on appointment of Rapporteurs for new ATMP applications.

## *Withdrawal of applications (section 2.8.)*

This section includes information on marketing authorisation applications that are withdrawn by the applicant. Applicants may decide to withdraw applications at any stage during the assessment and a CAT opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

## *Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004 (section 2.9.)*

This section lists applications for new marketing authorisation for ATMPs for which the applicant has requested a re-examination of the opinion previously issued by the CHMP. Similar to the initial evaluation of a marketing authorisation of an ATMP, CAT will adopt a draft re-examination opinion, which is transmitted to the CHMP for final adoption.

## *Companion diagnostics (section 2.10)*

This section lists applications for initial and follow-on consultation of companion diagnostics.

## *Post-authorisation activities (section 2.11-2.13.)*

Section 2.11 lists type II variations, including extension of indication applications and re-examination procedures for type II variations for which the applicant has requested re-examination of the opinion previously issued by the CHMP. Section 2.12 list extension application according to Annex I of Reg. 1234/2008 and section 2.13 includes all other post-authorisation activities concerning authorised ATMPs that are not covered elsewhere in the agenda such as post-authorisation measures, annual reassessments, 5-year renewals, supply shortages, qualify defects. Issues that have been discussed at the previous meeting of the PRAC, the EMA's committee responsible for evaluating and monitoring safety issues for medicines, will also be included here.

## *GMP and GCP Inspections Issues (section 2.14.)*

This section lists inspections that are undertaken for ATMPs. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

## **Certification of ATMPs (section 3)**

This section includes the scientific evaluation by the CAT of quality and non-clinical data that small and medium-sized enterprises have generated at any stage of the ATMP development process. More information on the ATMP certification procedure can be found [here](#).

## **Scientific Recommendation on Classification of ATMPs (Section 4)**

This section includes the scientific recommendation by the CAT on whether medicines based on genes, cells or tissues meet the scientific criteria that define ATMPs. More information on the ATMP classification procedure, including the outcomes of finalised classifications, can be found [here](#).

## **Scientific Advice (section 5)**

This section includes all scientific advice given to companies during the development of an ATMP. Information related to the number of ATMP related scientific advices discussed by CAT can be found in the CAT Monthly reports. Further information on SAWP can be found [here](#).

## **Pre-Authorisation (section 6)**

### *Paediatric Investigation Plan (PIP)*

This section includes the discussion of an ATMP before a formal application for marketing authorisation is submitted. These cases refer for example to requests for an accelerated assessment for medicines that are of major interest for public health or can be considered a therapeutic innovation: in case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

CAT contributes to the evaluation of a Paediatric Investigation Plan (PIPs) for ATMPs by the Paediatric Committee. These PIPs are included in this section of the Agenda.

### *ITF Briefing meeting in the field of ATMPs*

This section refers to briefing meetings of the Innovation Task Force and International co-operations activities of the CAT.

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes of meetings with applicants developing ATMPs and of other ITF meetings of interest to the CAT are included in this section of the agenda. Further information on the ITF can be found [here](#).

### *Priority Medicines (PRIME)*

This section includes the new requests for eligibility to PRIME for ATMPs under development, the discussions in CAT of these eligibility requests and the final recommendations for eligibility of ATMPs adopted by CHMP.

CAT will appoint one of its members as the CAT sponsor for each new ATMP eligibility request who will lead the CAT discussion based on the recommendation from the SAWP.

## **Organisational, regulatory and methodological matters (section 7)**

This section includes topics related to regulatory and procedural guidance, CAT workplan, CAT meeting organisation (including CAT membership), planning and reporting, co-ordination with other committees, working parties and scientific advisory groups.

Furthermore, this section refers to the activities of the CAT drafting groups developing scientific guidelines for gene therapy medicinal products and for cell-based medicinal products, cooperation within

the EU regulatory network and international regulators as well as direct interaction with interested parties. It also includes topics of scientific interest for the Committee that are not directly related to the work of the CAT drafting groups or CAT associated working parties.

## **Any other business (section 8)**

This section is populated with miscellaneous topics not suitable under the previous headings.

More detailed information on the above terms can be found on the EMA website: [www.ema.europa.eu/](http://www.ema.europa.eu/)